Centro de Cáncer de Cabeza y Cuello - Ensayos clínicos - Mayo Clinic

COVID-19 consejos información actualizada y opciones de vacunas

Infórmate sobre la COVID-19 y las vacunas contra esta enfermedad, y conoce las novedades para pacientes y visitantes de Mayo Clinic. Para navegación del sitio Para acceso a contenido Este contenido no tiene una versión en inglésEste contenido no tiene una versión en árabe Search Pida una consulta Para encontrar un doctor Para encontrar trabajo Para donar Acceso a su cuenta de paciente Español English العربية 简体中文 Twitter Facebook Pinterest YouTube Menú Solicite una Consulta Departamentos y centros Centros y departamentos médicos

Centro de Cáncer de Cabeza y Cuello

Ensayos clínicos

A continuación, se enumeran los ensayos clínicos actuales.
22 estudios en Centro de Cáncer de Cabeza y Cuello
(solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc.

Randomized Phase II III Trial of Adjuvant Radiation Therapy with Cisplatin Docetaxel-Cetuximab or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

Rochester, Minn. This randomized phase II/III trial studies how well radiation therapy works when given together with cisplatin compared to docetaxel or cetuximab and docetaxel after surgery in treating patients with stage III-IV squamous cell head and neck cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or transmit tumor killing molecules to them. It is not yet known whether radiation therapy is more effective when given with cisplatin, docetaxel, or cetuximab and docetaxel.

A Study to Evaluate Fractionated Radiation Therapy Utilizing GRID Therapy for Locally-advanced Bulky Tumors

Rochester, Minn., Jacksonville, Fla. The purpose of this research is to study radiographic control at the 3 month time-point, the side effects (good & bad), survival outcomes and proof of this idea in patients who have had grid therapy for locally advanced bulky tumors of the heat and neck, thorax, abdomen and extremities.

Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients with Advanced Solid Tumors

Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to demonstrate the safety and tolerability of JAB-3312 in combination with anti-PD-1 mAb or MEKi or KRASi or EGFR-TKI in patients with advanced solid tumors.

Cardiotoxic Effects of Chemotherapy in Patients with Sarcomas

Rochester, Minn. The purpose of this study is to determine if two-dimensional speckle tracking echocardiography (2D-STE) derived-strain can detect early myocardial dysfunction and thus predict cardiotoxicity in sarcoma subjects undergoing anthracycline therapy and to compare three dimensional speckle tracking echocardiography (3D-STE) to 2D-STE in the same group of patients.

A Study to Evaluate Endoscopic Endonasal Skull Base Surgery and Pituitary Surgery Quality of Life

Rochester, Minn. The objectives of this study are to: Measure the short and long-term overall and nasal-specific quality of life (QOL) impact of patients undergoing Endoscopic Endonasal Skull Base Surgery (EESBS) for pituitary and sellar lesions. Determine the relative difference in QOL impact of EESBS for patients undergoing surgery for functional and nonfunctional pituitary adenomas. Generate baseline data to development and validate a site-specific endoscopic-specific comprehensive QOL for EESBS. Particular tumors of interest include pituitary tumors, Rathke’s cleft cysts, craniopharyngiomas, clival chordomas and chondrosarcomas. Specific QOL aims focus on olfaction (sense of smell), gustation (sense of taste) and nasal function.

Effect of Agent Orange Exposure on Endocrine Tumor Aggressiveness

Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The intent is to collect relevant clinical data on patients exposed to Agent Orange plus assessment of the tissue for genetic mutations known to be associated with growth of thyroid cancer and pituitary tumors and report our findings as a descriptive case series.

Otorhinolaryngology Normal Tumor Tissue Saliva Stool and Blood Bank

Rochester, Minn. The purpose of this study is to obtain tissue, blood, saliva, and stool specimens and informed consent from ENT patients in order to build a freezer archive of samples to support ongoing and future developmental studies.

A Study of Sonidegib and Pembrolizumab in Advanced Solid Tumors

Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The purpose of this study is to determine the maximum tolerated dose (MTD) of sonidegib in combination with pembrolizumab in participants with advanced solid tumors as part of the dose escalation phase, and to estimate the response rate of sonidegib in combination with pembrolizumab in participants with NSCLC or pancreas cancer as part of the expansion cohort based on RECIST criteria.

A Study of the Impact of the Terminology Used to Identify Papillary Thyroid Cancer on the Treatment Options Chosen by Patients

Rochester, Minn. The purpose of this study is to explore how using different terms (with or without the word cancer) to identify papillary thyroid cancer might affect the decisions patients would make about treatment.

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Rochester, Minn. There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if there is no detectable EBV DNA in their plasma, then patients are randomized to either standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and fluorouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in treating patients with nasopharyngeal cancer. Solicite una Consulta en Mayo Clinic Sedes, viajes & alojamientoInvestigación Jan. 07, 2022 Comparte en: FacebookTwitter A continuación, se enumeran los ensayos clínicos actuales.
22 estudios en Centro de Cáncer de Cabeza y Cuello
(solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc.

Randomized Phase II III Trial of Adjuvant Radiation Therapy with Cisplatin Docetaxel-Cetuximab or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

Rochester, Minn. This randomized phase II/III trial studies how well radiation therapy works when given together with cisplatin compared to docetaxel or cetuximab and docetaxel after surgery in treating patients with stage III-IV squamous cell head and neck cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or transmit tumor killing molecules to them. It is not yet known whether radiation therapy is more effective when given with cisplatin, docetaxel, or cetuximab and docetaxel.

A Study to Evaluate Fractionated Radiation Therapy Utilizing GRID Therapy for Locally-advanced Bulky Tumors

Rochester, Minn., Jacksonville, Fla. The purpose of this research is to study radiographic control at the 3 month time-point, the side effects (good & bad), survival outcomes and proof of this idea in patients who have had grid therapy for locally advanced bulky tumors of the heat and neck, thorax, abdomen and extremities.

Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients with Advanced Solid Tumors

Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to demonstrate the safety and tolerability of JAB-3312 in combination with anti-PD-1 mAb or MEKi or KRASi or EGFR-TKI in patients with advanced solid tumors.

Cardiotoxic Effects of Chemotherapy in Patients with Sarcomas

Rochester, Minn. The purpose of this study is to determine if two-dimensional speckle tracking echocardiography (2D-STE) derived-strain can detect early myocardial dysfunction and thus predict cardiotoxicity in sarcoma subjects undergoing anthracycline therapy and to compare three dimensional speckle tracking echocardiography (3D-STE) to 2D-STE in the same group of patients.

A Study to Evaluate Endoscopic Endonasal Skull Base Surgery and Pituitary Surgery Quality of Life

Rochester, Minn. The objectives of this study are to: Measure the short and long-term overall and nasal-specific quality of life (QOL) impact of patients undergoing Endoscopic Endonasal Skull Base Surgery (EESBS) for pituitary and sellar lesions. Determine the relative difference in QOL impact of EESBS for patients undergoing surgery for functional and nonfunctional pituitary adenomas. Generate baseline data to development and validate a site-specific endoscopic-specific comprehensive QOL for EESBS. Particular tumors of interest include pituitary tumors, Rathke’s cleft cysts, craniopharyngiomas, clival chordomas and chondrosarcomas. Specific QOL aims focus on olfaction (sense of smell), gustation (sense of taste) and nasal function.

Effect of Agent Orange Exposure on Endocrine Tumor Aggressiveness

Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The intent is to collect relevant clinical data on patients exposed to Agent Orange plus assessment of the tissue for genetic mutations known to be associated with growth of thyroid cancer and pituitary tumors and report our findings as a descriptive case series.

Otorhinolaryngology Normal Tumor Tissue Saliva Stool and Blood Bank

Rochester, Minn. The purpose of this study is to obtain tissue, blood, saliva, and stool specimens and informed consent from ENT patients in order to build a freezer archive of samples to support ongoing and future developmental studies.

A Study of Sonidegib and Pembrolizumab in Advanced Solid Tumors

Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The purpose of this study is to determine the maximum tolerated dose (MTD) of sonidegib in combination with pembrolizumab in participants with advanced solid tumors as part of the dose escalation phase, and to estimate the response rate of sonidegib in combination with pembrolizumab in participants with NSCLC or pancreas cancer as part of the expansion cohort based on RECIST criteria.

A Study of the Impact of the Terminology Used to Identify Papillary Thyroid Cancer on the Treatment Options Chosen by Patients

Rochester, Minn. The purpose of this study is to explore how using different terms (with or without the word cancer) to identify papillary thyroid cancer might affect the decisions patients would make about treatment.

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Rochester, Minn. There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if there is no detectable EBV DNA in their plasma, then patients are randomized to either standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and fluorouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in treating patients with nasopharyngeal cancer.

Centro de Cáncer de Cabeza y Cuello

Página inicial del departamentoSeccionesPanorama generalAnálisis y procedimientosEnfermedades que se tratanMédicosMédicos por sede y especialidadGrupos especializadosPericia & clasificacionesSedes, viajes & alojamientoEnsayos clínicosInvestigaciónExperiencia en Mayo Clinic e historias de pacientesCostos & seguro médicoNoticias de Mayo ClinicRemisiones

Investigación todo es por los pacientes

Secciones

Solicite una ConsultaPanorama generalAnálisis y procedimientosEnfermedades que se tratanMédicosMédicos por sede y especialidadGrupos especializadosPericia & clasificacionesSedes, viajes & alojamientoEnsayos clínicosInvestigaciónExperiencia en Mayo Clinic e historias de pacientesCostos & seguro médicoNoticias de Mayo ClinicRemisiones ORG-20456033 Departamentos y centros Centros y departamentos médicos Centro de Cáncer de Cabeza y Cuello